The three co-opted E3 ligases, VHL, XIAP, and AHR, have been explored against cancer targets in PROTAC12,22,44–46, and their expression patterns in tumor and normal tissues suggest extensive future usage, such as XIAP in breast cancer (Fig. 4c, Supplementary Fig. 10). This evidence concerns the gene AHR and breast carcinoma.